Roundtable Discussions
Where Are We Now and Where Are We Heading? Cell and Gene Therapy in 2022

Roundtable Discussions

27 Jan 2022
Plenary Room
Cook MyoSite
Fujifilm Irvine Scientific
Minaris Regenerative Medicine
Gemini Bio-Products
Bioprocess Insider
Fresenius Kabi
L7 Informatics

Roundtable Discussion 1
Hosted by Dan Stanton, Founder and Editor, BioProcess Insider

Roundtable Discussion 2: Understanding of the Principles of Cryopreservation and How They Impact Cell & Gene Therapy Development and Subsequent Manufacturability

Discuss key components to cryopreservation process from source materials to cell banks to final product

  • Areas for optimization
  • Reagent quality and relevant regulations
  • Steps towards standardization

Hosted by Dominic Clarke, Chief Technical Officer, for Cell & Gene Therapies at Discovery Life Sciences

Roundtable Discussion 3: Treatment Development Paradigm for Quality of Life conditions: Regulatory Considerations & Collaborative Ecosystem

  • “Just” QOL – call to re-examine the attention and nomenclature towards life-altering conditions.
  • Fast track/accelerated approval standards for life-altering vs. life-threatening conditions – how can we build a path to ensure equitable considerations?
  • Potential impact to future investments for the development of treatments for life-altering conditions in current regulatory landscape.
  • Getting started – how can conferences like this also promote a “Collaborative Ecosystem” for life-altering disorders?

Hosted by Ryan Pruchnic, Managing Vice President, Cook Myosite

Roundtable Discussion 4
Hosted by Jo Anne Valentino, Chief Operating Officer, Minaris Regenerative Medicine

Roundtable Discussion 5
Hosted by Millipore Sigma

Roundtable Discussion 6: Patient Centricity And The Improvement Of The Entire End-To-End Supply Chain
Hosted by Time:Matters

Roundtable Discussion 7: Exploring Bedside Autologous CGT Manufacturing

  • Allogeneic therapies (in concept) have a huge economic advantage over autologous therapies. What does the future of autologous therapies need to look like in order to make economic sense?
  • What portions of the manufacturing workflow are amenable to be done at the point of collection?
  • What technology gaps need to be overcome to enable more/all of the CGT workflow to occur at the point of collection? At the bedside?
  • What biology gaps need to be overcome to enable more/all of the CGT workflow to occur at the point of collection? At the bedside?
  • What are the limitations of bedside QC release? Does this change if you view the therapy as a procedure instead of a single-dose drug?

Hosted by Chris Wegener, Director, Cell Therapy R&D, Fresenius Kabi

Roundtable Discussion 8
Hosted by L7 Informatics


Jo Anne Valentino
Chief Operating Officer
Minaris Regenerative Medicine
Dan Stanton
Founder and Editor
Bioprocess Insider